Compare · WST vs XRAY
WST vs XRAY
Side-by-side comparison of West Pharmaceutical Services Inc. (WST) and DENTSPLY SIRONA Inc. (XRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both WST and XRAY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 11.1x XRAY ($2.00B).
- Over the past year, WST is up 40.5% and XRAY is down 38.3% - WST leads by 78.8 points.
- XRAY has been more active in the news (16 items in the past 4 weeks vs 4 for WST).
- XRAY has more recent analyst coverage (25 ratings vs 16 for WST).
- Company
- West Pharmaceutical Services Inc.
- DENTSPLY SIRONA Inc.
- Price
- $314.41-0.90%
- $10.01+1.42%
- Market cap
- $22.22B
- $2.00B
- 1M return
- +0.26%
- -10.22%
- 1Y return
- +40.47%
- -38.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 4
- 16
- Recent ratings
- 16
- 25
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
Latest XRAY
- Director Lucier Gregory T received a gift of 38,382 shares, was granted 38,382 shares and gifted 38,382 shares (SEC Form 4)
- Director Zurbay Donald was granted 22,822 shares, increasing direct ownership by 332% to 29,693 units (SEC Form 4)
- Director Vergis Janet S. was granted 22,822 shares, increasing direct ownership by 51% to 67,324 units (SEC Form 4)
- Director Varon Leslie F was granted 22,822 shares, increasing direct ownership by 40% to 80,364 units (SEC Form 4)
- Director Mckeon Brian P was granted 28,887 shares (SEC Form 4)
- Director Mazelsky Jonathan Jay was granted 22,822 shares, increasing direct ownership by 79% to 51,669 units (SEC Form 4)
- Director Hosein Clyde was granted 22,822 shares, increasing direct ownership by 55% to 64,075 units (SEC Form 4)
- Director Holden Betsy D was granted 22,822 shares, increasing direct ownership by 42% to 77,442 units (SEC Form 4)
- Director Gladden Brian T was granted 22,822 shares, increasing direct ownership by 79% to 51,864 units (SEC Form 4)
- Director Forbes James D was granted 28,887 shares, increasing direct ownership by 289% to 38,887 units (SEC Form 4)